NewKerala.com

Key Points

The Emirates Drug Establishment has achieved a global first by approving Tolebrutinib for non-relapsing secondary progressive multiple sclerosis. This oral treatment uniquely targets disability progression regardless of relapses by addressing chronic neuroinflammation in the central nervous system. The approval resulted from collaborative efforts with the National Multiple Sclerosis Society and reflects the UAE's proactive regulatory policies. This milestone demonstrates the nation's commitment to accelerating access to innovative therapies that significantly improve patient outcomes.

Key Points: Emirates Drug Establishment Approves First Global Tolebrutinib for SPMS

  • First oral treatment approved globally for non-relapsing secondary progressive MS
  • Targets B cells and microglia to address chronic neuroinflammation
  • Developed through collaboration with National Multiple Sclerosis Society
  • UAE's flexible regulatory ecosystem accelerated patient access to innovation
3 min read

Emirates Drug Establishment grants global first approval for 'Tolebrutinib'

UAE makes history with world's first approval of Tolebrutinib, the only oral treatment targeting disability progression in non-relapsing secondary progressive MS.

"The approval of Tolebrutinib marks a transformative step in addressing one of the most complex neurological diseases. - Fatima Al Kaabi, Director-General of Emirates Drug Establishment"

Abu Dhabi, August 26

In a landmark regulatory achievement that reflects the UAE's leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of "Tolebrutinib" as the world's first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS).

This milestone underscores the nation's commitment to providing advanced, science-based therapeutic solutions that enhance patients' quality of life and align with global healthcare advancements.

The approval was based on a scientific study conducted in collaboration with the National Multiple Sclerosis Society. Tolebrutinib is currently the only treatment that directly targets disability progression regardless of relapses, supporting evidence-based regulatory decisions and improving care quality for MS patients in the UAE.

Tolebrutinib was developed as an oral inhibitor that targets specific immune cells within the central nervous system, namely B cells and microglia, which are believed to play a key role in disease progression. By addressing underlying chronic neuroinflammation, the treatment introduces a novel approach that tackles the root cause of disability accumulation independently of relapses, a breakthrough not achieved by previous therapies.

Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, emphasised that this approval reflects the success of the UAE's proactive policies in fostering a flexible regulatory ecosystem that supports innovation and expedites patient access to advanced treatments.

She stated, "The approval of Tolebrutinib marks a transformative step in addressing one of the most complex neurological diseases. It embodies our commitment to accelerating access to innovative therapies that make a real difference in patients' lives. We are dedicated to adopting a forward-thinking approach rooted in innovation and global partnerships, ensuring the availability of safe and effective treatment options that meet the highest international standards."

"This approval is the result of collaborative efforts between the Establishment and its international partners to support scientific innovation and translate it into real-world patient benefit. At the Emirates Drug Establishment, we believe in fast-tracking regulatory processes in areas of high medical need. This achievement reaffirms the readiness of our healthcare system to keep pace with rapid scientific advancements and deliver high-quality treatments that enhance quality of life and strengthen national health security."

In this context, the partnership with the National Multiple Sclerosis Society marks a pivotal moment in the development of targeted therapies for patients with progressive MS, culminating in the approval of the first treatment to directly address the mechanisms of disability progression independent of relapses.

The adoption of this advanced scientific approach, coupled with effective collaboration, underscores the UAE's leadership in accelerating access to scientific innovation. It also reflects the Emirates Drug Establishment's genuine commitment to improving patients' outcomes and expanding access to evidence-based care. (ANI/WAM)

- ANI

Share this article:

Reader Comments

R
Rohit P
Great to see Middle Eastern countries taking leadership in medical research. This oral treatment could be a game-changer for MS patients worldwide. Hope Indian regulators also fast-track such innovations.
A
Arjun K
While this is impressive, I hope the pricing will be reasonable. Many advanced treatments remain inaccessible to common people due to high costs. Hope they consider affordability alongside innovation.
S
Sarah B
As someone with MS, this gives me hope! Targeting the root cause rather than just symptoms is exactly what we need. Wishing all the best to the researchers and patients who will benefit from this.
V
Vikram M
UAE is becoming a medical tourism hub. First approvals like this will attract patients from across Asia and Africa. Good for their economy and good for patients who need advanced treatments.
N
Nikhil C
Hope Indian pharmaceutical companies are paying attention. We need to invest more in R&D for neurological disorders rather than just generic manufacturing. Time to step up our game!

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50